IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-13. Numbers and descriptions here follow the published literature rather than marketing material.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
== Plot == A homeless Ren and Stimpy are caught again and sent to the dog pound, where they are sent to their imminent death. They are saved by an unnamed rich and senile lady (Granny) on the verge of death while a priest ordains them in a gas chamber. The duo feed themselves in Granny's limousine, grateful of their survival, when the woman decides to name them "Abraham" and "Levictus" which they reluctantly allow. The duo settle at their new home. Ren decides to shake hands with a dog he believes is a fellow pet. At first, Ren assumes the dog is sleeping and attempts to wake him up, only to discover that he is dead; Granny explains that the dog is a previous pet of hers named Ezekiel who died in his sleep, so his corpse was freeze-dried in a successful attempt of taxidermy. Suddenly, the duo are condemned by the lady for being apparently possessed, despite acting normal for their kind, as they are handed off to the lady's butler Mr. Hao, a stereotypical Chinese muscular man who beats them to a pulp. The duo, who cannot walk normally after the beating, are forced to eat literal rocks advertised as dog food. Ren breaks his teeth doing so while Stimpy chokes on it; Ren's unsuccessful attempt of the Heimlich maneuver is seen as a threat by Granny, who sprays Stimpy with water and forces him to spit. She sends them to a veterinarian who further harms them. The duo sleep in the living room when Granny forcibly moves them to the yard; they find that it is a cemetery for her pets.
Radium was discovered by Marie Skłodowska-Curie and her husband Pierre Curie on 21 December 1898 in a uraninite (pitchblende) sample from Jáchymov. While studying the mineral earlier, the Curies removed uranium from it and found that the remaining material was still radioactive. In July 1898, while studying pitchblende, they isolated an element similar to bismuth which turned out to be polonium. They then isolated a radioactive mixture consisting of two components: compounds of barium, which gave a brilliant green flame color, and unknown radioactive compounds which gave carmine spectral lines that had never been documented before. The Curies found the radioactive compounds to be very similar to the barium compounds, except they were less soluble. This discovery made it possible for the Curies to isolate the radioactive compounds and discover a new element in them. The Curies announced their discovery to the French Academy of Sciences on 26 December 1898. The naming of radium dates to about 1899, from the French word radium, formed in Modern Latin from radius (ray): this was in recognition of radium's emission of energy in the form of rays. The gaseous emissions of radium, radon, were recognized and studied extensively by Friedrich Ernst Dorn in the early 1900s, though at the time they were characterized as "radium emanations". In September 1910, Marie Curie and André-Louis Debierne announced that they had isolated radium as a pure metal through the electrolysis of pure radium chloride (RaCl2) solution using a mercury cathode, producing radium–mercury amalgam.
== Short-term feed restriction == Recent studies on short-term effects of a meal or the absence of a meal has revealed that lepa1 expression specifically peaks in the peripheral tissues after 6 – 9 hr in the unfed fish. This suggests that the transcript specific response could be associated with the absence of food. Conversely, since the unfed fish had not received food for 33 hr (24 + 9 hr), the peaks could represent an unrelated effect. Each lepa1 peak occurred during a phase of falling plasma Lep, and since this occurred in both fed and unfed fish, the temporal upregulation of lepa1 does not in fact appear to be specifically related to the absence of food. The earliest peak of lepa1 occurred in the white muscle, which represents an important lipid reservoir in Atlantic salmon. Unlike pufferfish, which utilizes the liver as a major lipid repository, Atlantic salmon shows that despite a high visceral lipid content, hepatocytes contain few lipid droplets compared to other fish species, yet are an important site for leptin expression. Moen and colleagues reported that both lepa1 and lepa2 peaked at 9 hr in the liver of unfed fish. By contrast, however, studies in common carp demonstrated a peak in leptin-I(lepa1) and leptin–II (lepa2) in liver at 3 and 6 hr post feeding respectively. The earlier expression response of leptins in common carp likely reflects the higher temperature under which the experiments were conducted, but contrasts the findings of upregulation of lepa1 due to the absence of food.
Bully: Brett Height: 5'8 Weight: 164 lb Victim(s): Zack Fighter: Abel Cullum Height: 5'7 Weight: 158 lb Money earned by Bully: $1000 Money earned by victim(s): $9000 Original airing: Friday October 4, 2012.
Sources: en.wikipedia.org
For services to Urban Regeneration. William James Ferguson, , lately Vice Chairman, Scottish Agricultural College. For services to Agriculture and to Education. Thelma Fisher, Director, National Family Mediation. For services to the community. David Fleming. For services to Museums. Douglas Munro Fleming, General Medical Practitioner, Birmingham. For services to Medicine. George Malcolm Fordy, Chairman and Chief Executive, FT Construction Group. For services to the Building Industry. Michael Hartley Foulds, Member, Association of Chartered Certified Accountants. For services to Accountancy. Major Roy Sutherland Fox. For services to the Soldiers', Sailors' and Airmen's Families Association in Suffolk. Stephen Giles Frankiss, Grade 6, Department of Transport. Jacqueline Dorothy Fuller, Officer in Charge, Board of Inland Revenue. Robert Alan Gailey. For services to Museums and Galleries. William Alistair Galston, lately Chief Inspector, Gaming Board of Great Britain. John Frederick Gibson, Secretary Scientific, Royal Society of Chemistry. For services to Chemistry. Thelma Joyce Gillen, Grade 7, Ministry of Defence. Michael John Goodman, Senior Group Leader, Pulse Power Research, AWE Aldermaston. For services to the Defence Industry. Gerard Graham. For services to the community in Tyne and Wear. William Grant, . For services to Environmental Protection and to the Arts. Frederick Howard Green, Education Adviser, National Association of Independent and non-Maintained Schools. For services to Special Needs Education.
By 1980, the BSAP comprised about 46,000 personnel; 11,000 professionals (about 60% black), and the remainder reservists (mostly white). The organisation's rank structure was unique, with different levels of seniority existing for black and white officers respectively. Until 1976, black officers could rise no further than sub-inspector, while the commissioned ranks were all-white. Limitations on black aspirations were removed in 1976. The first promotion of African members to previously European-only ranks occurred on 21 October 1976 with 23 Sub-Inspectors and 8 Detective Sub-Inspectors, a week later, being promoted to Patrol Officers.
A sovereign can never abdicate. He can be deposed... All right. That is force. But abdicate – never, never, never! I would rather fall here at your side. Then there would be Otto. And even if all of us here were killed, there would still be other Habsburgs! Charles gave his permission for the document to be published, and he, his family and the remnants of his Court departed for the Royal shooting lodge at Eckartsau, close to the borders with Hungary and Slovakia. The Republic of German-Austria was proclaimed the next day.
Enzymatic browning is one of the most important reactions that takes place in most fruits and vegetables as well as in seafood. These processes affect the taste, color, and value of such foods. Generally, it is a chemical reaction involving polyphenol oxidase (PPO), catechol oxidase, and other enzymes that create melanins and benzoquinone from natural phenols. Enzymatic browning (also called oxidation of foods) requires exposure to oxygen. It begins with the oxidation of phenols by polyphenol oxidase into quinones, whose strong electrophilic state causes high susceptibility to a nucleophilic attack from other proteins. These quinones are then polymerized in a series of reactions, eventually resulting in the formation of brown pigments (melanosis) on the surface of the food. The rate of enzymatic browning is reflected by the amount of active polyphenol oxidases present in the food. Hence, most research into methods of preventing enzymatic browning has been directed towards inhibiting polyphenol oxidase activity. However, not all browning of food produces negative effects. Examples of beneficial enzymatic browning:
=== Anticodon === An anticodon is a unit of three nucleotides corresponding to the three bases of an mRNA codon. Each tRNA has a distinct anticodon triplet sequence that can form 3 complementary base pairs to one or more codons for an amino acid. Some anticodons pair with more than one codon due to wobble base pairing. Frequently, the first nucleotide of the anticodon is one not found on mRNA: inosine, which can hydrogen bond to more than one base in the corresponding codon position. In genetic code, it is common for a single amino acid to be specified by all four third-position possibilities, or at least by both pyrimidines and purines; for example, the amino acid glycine is coded for by the codon sequences GGU, GGC, GGA, and GGG. Other modified nucleotides may also appear at the first anticodon position—sometimes known as the "wobble position"—resulting in subtle changes to the genetic code, as for example in mitochondria. The possibility of wobble bases reduces the number of tRNA types required: instead of 61 types with one for each sense codon of the standard genetic code), only 31 tRNAs are required to translate, unambiguously, all 61 sense codons.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.